Peter Finan

Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom.

Keystone Symposia operates as a catalyst for the advancement of biomedical and life sciences by connecting scientists within and across disciplines at conferences and workshops. The company was founded by C. Fred Fox in 1972 and is headquartered in Silverthorne, CO.

Adorx Therapeutics Ltd. provides biotechnology, health care and therapeutics services. The company is headquartered in Edinburgh, the United Kingdom.

Epsilogen Ltd. engages in the development of immunoglobulin E (IgE) antibodies to treat cancer. The firm offers IGEG platform technology based on combining the power of IgE and Immunoglobulin G (IgG) antibody molecules. The company was founded by Sophia Karagiannis and James Spicer and is headquartered in London, United Kingdom.

Epidarex Capital Partners LLC (Epidarex Capital) is a venture capital firm founded in 2010 by Kyparissia Sirinakisvin. The firm is headquartered in Bethesda, Maryland.

Lunac Therapeutics Ltd. engages in the identification and development of anticoagulants. The company was founded by Helen Philippou and Richard Foster on April 18, 2018 and is headquartered in Leeds, the United Kingdom.

Topas Therapeutics GmbH engages in pharmaceutical preparations. The company is headquartered in Hamburg, Germany.

Clyde Biosciences Ltd. provides developmental drug testing services. It offers drug screening, toxicity data analysis, direct measurements, and drug induced changes investigation services. Its services include calcium, voltage, contractility, in silico modeling, CiPA studies and bespoke R&D. The company was founded by Margaret Anne Craig, Godfrey Smith, Francis Burton, and Jon Cooper on March 9, 2012 and is headquartered in Glasgow, the United Kingdom.

Leucid Bio Ltd. is a clinical-stage biotechnology company based in London, UK. The British company develops novel, lateral car cell therapies for the treatment of refractory cancers, with a focus on developing next-generation cell therapies for the benefit of individuals with hard-to-treat solid tumors. The company's operations are based at Guys Hospital, enabling them to maintain a patient-centric focus. Leucid's goal is to develop CAR-T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers. Leucid was established to translate 20 years of Kings College research in the CAR-T field and is led by a highly experienced management team, including scientific founder John Maher. Filippo Joseph Petti has been the CEO of the company since 2023.